SEMAX (10mg)

Semax, a pharmaceutical developed in Russia, has demonstrated efficacy in the management of stroke, cognitive impairment, dementia, and inflammation of the optic nerve. Additionally, it has undergone evaluation as a potential immunostimulant and has exhibited properties linked to alleviating symptoms of depression and anxiety. Research has established that Semax elevates levels of brain-derived neurotrophic factor (BDNF) within the central nervous system, while also influencing serotonin and dopamine levels.

Semax, a pharmaceutical developed in Russia, has demonstrated efficacy in the management of stroke, cognitive impairment, dementia, and inflammation of the optic nerve. Additionally, it has undergone evaluation as a potential immunostimulant and has exhibited properties linked to alleviating symptoms of depression and anxiety. Research has established that Semax elevates levels of brain-derived neurotrophic factor (BDNF) within the central nervous system, while also influencing serotonin and dopamine levels.

The hormone leptin, commonly known as the "satiety hormone," plays a pivotal role in signaling satiety to the brain and thereby regulating weight in various mammalian species. Research suggests that orexin, another hormone, may exert effects that either imitate those of leptin or potentially surpass leptin in potency. Additionally, studies have linked orexin depletion to diminished energy expenditure in mice. Consequently, orexin may wield a more substantial influence on hunger and energy expenditure compared to leptin. This assertion aligns with existing evidence that highlights the correlation between sleep and heightened hunger, as well as the limited efficacy of therapeutics targeting leptin receptors in the treatment of obesity.

DISCLAIMER: FOR EXPERIMENTAL USE ONLY, NOT FOR PERSONAL USE